An investigation on behalf of investors in Vistagen Therapeutics Inc (NASDAQ:VTGN) shares over potential wrongdoing at Vistagen Therapeutics was announced and NASDAQ:VTGN stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 10/02/2017 --An investigation on behalf of investors in shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) was announced over potential breaches of fiduciary duties by certain officers and directors at Vistagen Therapeutics.

Investors who purchased shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm concerns whether certain Vistagen Therapeutics Inc (NASDAQ:VTGN officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

San Franciscom, CA based VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Shares of Vistagen Therapeutics Inc (NASDAQ:VTGN) declined from $16.00 per share in June 2015 to as low as $1.53 per share on September 26, 2017.

Those who purchased shares of Vistagen Therapeutics Inc (NASDAQ:VTGN), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com